These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8139583)

  • 1. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
    Zalman LS; Müller-Eberhard H
    Mol Immunol; 1994 Mar; 31(4):301-5. PubMed ID: 8139583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
    Zalman LS; Wood LM; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6975-9. PubMed ID: 2428045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
    Sims PJ
    Biochim Biophys Acta; 1983 Aug; 732(3):541-52. PubMed ID: 6871214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL; Monahan JB; Brickner A; Sodetz JM
    Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor.
    Young JD; Jiang S; Liu CC; Hasselkus-Light CS
    J Immunol Methods; 1990 Mar; 128(1):133-42. PubMed ID: 1691232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.
    Podack ER; Tschoop J; Müller-Eberhard HJ
    J Exp Med; 1982 Jul; 156(1):268-82. PubMed ID: 6177822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
    Houle JJ; Hoffmann EM; Esser AF
    Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9.
    Ninomiya H; Sims PJ
    J Biol Chem; 1992 Jul; 267(19):13675-80. PubMed ID: 1377690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes.
    Zalman LS; Wood LM; Müller-Eberhard HJ
    J Exp Med; 1987 Oct; 166(4):947-55. PubMed ID: 3655659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
    Davé SJ; Sodetz JM
    J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
    Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T; Morgan BP; Meri S
    Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T; Meri S
    J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J; Chonn A; Hertig S; French LE
    J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
    Rosenfeld SI; Packman CH; Leddy JP
    J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.